No products in the cart.
Pre-made Lorvotuzumab benchmark antibody ( Whole mAb ADC, anti-NCAM1 therapeutic antibody, Anti-CD56/NCAM/MSK39 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-323
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lorvotuzumab biosimilar, Whole mAb ADC, Anti-NCAM1 Antibody: Anti-CD56/NCAM/MSK39 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lorvotuzumab mertansine is designed for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer). It has been granted orphan drug status for Merkel cell carcinoma and has reported encouraging Phase II results for small-cell lung cancer (SCLC).
| Products Name (INN Index) | Pre-Made Lorvotuzumab biosimilar, Whole mAb ADC, Anti-NCAM1 Antibody: Anti-CD56/NCAM/MSK39 therapeutic antibody |
|---|---|
| INN Name | Lorvotuzumab |
| Target | NCAM1 |
| Format | Whole mAb ADC |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | ImmunoGen |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Multiple myeloma,Solid tumours,Small cell lung cancer,Haematological malignancies |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | NCAM1 |
| Package |
Previous slide
Next slide
